First Quadrant’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-343
| Closed | -$15K | – | 502 |
|
|
2021
Q3 | $15K | Hold |
343
| – | – | ﹤0.01% | 502 |
|
|
2021
Q2 | $15K | Sell |
343
-2,693
| -89% | -$115K | ﹤0.01% | 499 |
|
|
2021
Q1 | $124K | Sell |
3,036
-1,046
| -26% | -$39.7K | 0.01% | 402 |
|
|
2020
Q4 | $185K | Hold |
4,082
| – | – | 0.02% | 362 |
|
|
2020
Q3 | $144K | Hold |
4,082
| – | – | 0.02% | 390 |
|
|
2020
Q2 | $154K | Buy |
4,082
+57
| +1% | +$1.88K | 0.02% | 464 |
|
|
2020
Q1 | $116K | Sell |
4,025
-5,192
| -56% | -$210K | 0.02% | 441 |
|
|
2019
Q4 | $478K | Buy |
9,217
+37
| +0.4% | +$2.15K | 0.04% | 318 |
|
|
2019
Q3 | $504K | Sell |
9,180
-847
| -8% | -$43.5K | 0.05% | 308 |
|
|
2019
Q2 | $407K | Hold |
10,027
| – | – | 0.03% | 431 |
|
|
2019
Q1 | $303K | Hold |
10,027
| – | – | 0.02% | 434 |
|
|
2018
Q4 | $337K | Hold |
10,027
| – | – | 0.03% | 426 |
|
|
2018
Q3 | $423K | Sell |
10,027
-3,373
| -25% | -$133K | 0.01% | 516 |
|
|
2018
Q2 | $429K | Hold |
13,400
| – | – | 0.01% | 508 |
|
|
2018
Q1 | $666K | Hold |
13,400
| – | – | 0.01% | 448 |
|
|
2017
Q4 | $722K | Hold |
13,400
| – | – | 0.01% | 490 |
|
|
2017
Q3 | $777K | Hold |
13,400
| – | – | 0.02% | 486 |
|
|
2017
Q2 | $661K | Hold |
13,400
| – | – | 0.01% | 497 |
|
|
2017
Q1 | $582K | Hold |
13,400
| – | – | 0.01% | 518 |
|
|
2016
Q4 | $656K | Hold |
13,400
| – | – | 0.01% | 502 |
|
|
2016
Q3 | $641K | Hold |
13,400
| – | – | 0.01% | 507 |
|
|
2016
Q2 | $719K | Hold |
13,400
| – | – | 0.02% | 438 |
|
|
2016
Q1 | $599K | Sell |
13,400
-1,300
| -9% | -$52.7K | 0.01% | 470 |
|
|
2015
Q4 | $561K | Buy |
14,700
+500
| +4% | +$19.1K | 0.01% | 459 |
|
|
2015
Q3 | $452K | Hold |
14,200
| – | – | 0.01% | 467 |
|
|
2015
Q2 | $469K | Sell |
14,200
-11,200
| -44% | -$399K | 0.01% | 478 |
|
|
2015
Q1 | $1.05M | Hold |
25,400
| – | – | 0.02% | 342 |
|
|
2014
Q4 | $1.03M | Hold |
25,400
| – | – | 0.02% | 349 |
|
|
2014
Q3 | $931K | Hold |
25,400
| – | – | 0.02% | 371 |
|
|
2014
Q2 | $1.18M | Buy |
25,400
+9,500
| +60% | +$422K | 0.03% | 358 |
|
|
2014
Q1 | $653K | Buy |
15,900
+1,700
| +12% | +$63.2K | 0.01% | 416 |
|
|
2013
Q4 | $542K | Sell |
14,200
-6,600
| -32% | -$204K | 0.01% | 455 |
|
|
2013
Q3 | $497K | Buy |
20,800
+3,300
| +19% | +$74.1K | 0.01% | 458 |
|
|
2013
Q2 | $298K | Buy |
+17,500
| New | +$252K | 0.01% | 498 |
|
Other funds holding ANIK
TI
First Quadrant's ANIK Position: Q4 2021 in Review
First Quadrant sold out of Anika Therapeutics (ANIK) in Q4 2021, closing a stake of 343 shares — an estimated $15K sold.
First Quadrant first reported a position in ANIK in Q2 2013 and held it in 34 quarters. The position peaked at $1.18M in Q2 2014. 127 funds tracked by Wall St. Rank hold ANIK as of Q4 2021.
- First Quadrant reported no remaining Anika Therapeutics position as of Q4 2021 after selling out during the quarter.
- First Quadrant sold 343 Anika Therapeutics shares in Q4 2021, an estimated $15K.
- First Quadrant first reported a position in Anika Therapeutics in Q2 2013 and held it in 34 quarters.
- First Quadrant's Anika Therapeutics position peaked at $1.18M in Q2 2014.
- 127 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2021.
Based on First Quadrant's 13F filing for Q4 2021, filed 27 Jan 2022.